RPI-1
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity[1].
Product Specifications
CAS Number
269730-03-2
UNSPSC
12352005
Hazard Statement
H400
Target
RET
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rpi-1.html
Purity
99.29
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C1NC2=C(C=C(OC)C(OC)=C2)/C1=C/C3=CC=C(O)C=C3
Molecular Formula
C17H15NO4
Molecular Weight
297.31
Precautions
P273-P391-P501
References & Citations
[1]Lanzi C, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci. 2003;60 (7) :1449-1459.|[2]Cuccuru G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96 (13) :1006-1014.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR10378040 96 Well
Rabbit Olfactory receptor 10K2 (OR10K2) ELISA kit
Sign In for Pricing
View Details 
EK341513 96 Well
Human XBP1 (X-Box Binding Protein 1) ValidElisa Kit
Sign In for Pricing
View Details 
28440066 1.0 µg DNA
MFF Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details